GLMD — Galmed Pharmaceuticals Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595353 ·
Last close
$0.62
Market Cap
$5.13M
52W High
$0.79
52W Low
$0.41
ADV30
705,280
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,044,000 | -1,910,000 | 16,027,000 | 1,600,000 | 2,079,000 |
| Dec 2025 | 0 | — | -3,042,000 | -4,818,000 | 18,627,000 | 3,985,000 | 2,845,000 |
| Sep 2025 | 0 | — | -2,095,000 | -1,892,000 | 21,584,000 | 3,314,000 | 2,472,000 |
| Jun 2025 | 0 | — | -2,109,000 | -2,495,000 | 22,944,000 | 4,964,000 | 2,421,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,315,000
Investing CF
$-3,375,000
Financing CF
$9,026,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-210,778,000
Inventory
—
Receivables
$80,000
ST Investments
$14,171,000
EBIT TTM
$-8,510,000
Pretax Income TTM
$-10,309,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,510,000 | -10,309,000 | 18,627,000 | 2,845,000 | — | -6,315,000 |
| Dec 2024 | 0 | -6,278,000 | -7,517,000 | 18,500,000 | 2,173,000 | — | -5,880,000 |
| Dec 2023 | 0 | -7,492,000 | -6,912,000 | 16,629,000 | 2,750,000 | — | -6,137,000 |
| Dec 2022 | 0 | -17,651,000 | -17,866,000 | 16,561,000 | 3,138,000 | — | -18,501,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APVO | Aptevo Therapeutics Inc. | $5.12M | $4.11 | — |
| HCWB | HCW Biologics Inc. | $5.11M | $3.20 | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.97M | $0.16 | — |
| JAGX | Jaguar Health, Inc. | $4.91M | $1.00 | — |
| RNAZ | Transcode Therapeutics, Inc. | $4.83M | $4.56 | — |
News headlines (Yahoo Finance, 1h cache)
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
2026-07-28 11:00 · Yahoo
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
2026-07-16 14:05 · Yahoo
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
2026-07-16 11:30 · Yahoo
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
2026-06-22 11:00 · Yahoo
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
2026-06-08 11:00 · Yahoo
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
2026-06-02 11:30 · Yahoo
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 3
2026-05-14 11:30 · Yahoo
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
2026-05-06 11:30 · Yahoo
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
2026-04-14 11:30 · Yahoo
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
2026-04-09 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.